Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435677 | 1.00 | TRPV4 (0.51) | TRPV4NFE2L2LMNASMN1; SMN2ACLY | |
| SCHEMBL5697437 | 0.86 | TRPV4 (0.42) | TRPV4NFE2L2LMNASMN1; SMN2MAPK1 | |
| SCHEMBL31634218 | 0.81 | NFE2L2 (0.46) | NFE2L2LMNASMN1; SMN2ACLYCA1 | |
| SCHEMBL3704196 | 0.81 | COMT (0.47) | NFE2L2LMNASMN1; SMN2ACLYALDH1A1 | |
| SCHEMBL1742387 | 0.81 | CA1 (0.56) | NFE2L2LMNASMN1; SMN2CA1CA2 | |
| SCHEMBL925929 | 0.81 | NFE2L2 (0.46) | NFE2L2LMNASMN1; SMN2ACLYCA1 | |
| SCHEMBL3698654 | 0.79 | COMT (0.46) | NFE2L2LMNASMN1; SMN2ACLYALDH1A1 | |
| SCHEMBL3713453 | 0.79 | COMT (0.46) | NFE2L2LMNASMN1; SMN2ACLYALDH1A1 | |
| SCHEMBL3698635 | 0.79 | COMT (0.46) | NFE2L2LMNASMN1; SMN2ACLYALDH1A1 | |
| Lithium Ion SCHEMBL3698633 | 0.79 | NFE2L2 (0.45) | TRPV4NFE2L2LMNASMN1; SMN2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425423-A | Positively charged composite membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| US-6943254-B2 | Synthesis of pyrazinyl pyridine-3-sulfonamide compounds | ASTRAZENECA UK LIMITED (GB) | 2005-09-13 | — | — | US | claimed |
| EP-0973704-B1 | PROCESS FOR THE MANUFACTURE OF ARYLSULFONYL CHLORIDE | ASTRAZENECA AB (SE) | 2004-10-06 | — | — | EP | claimed |
| US-20030162973-A1 | Process for the manufacture of arylsulfonyl chloride | ASTRAZENECA UK LIMITED (GB) | 2003-08-28 | — | — | US | claimed |
| US-6531605-B1 | Reacting diazonium salt of aminopyridine or aminobenzene with thionyl chloride in water, electron transfer catalyst; 2-chloropyridine-3-sulfonyl chloride; avoids use of acetic acid and sulfur dioxide; no extraction isolation problems | ZENECA LIMITED (GB) | 2003-03-11 | — | — | US | claimed |
| EP-0973704-A1 | PROCESS FOR THE MANUFACTURE OF ARYLSULFONYL CHLORIDE | ZENECA LIMITED (GB) | 2000-01-26 | — | — | EP | claimed |
| WO-1998040332-A1 | PROCESS FOR THE MANUFACTURE OF ARYLSULFONYL CHLORIDE | ZENECA LIMITED (GB) | 1998-09-17 | — | — | WO | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-11 | — | — | US | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| EP-4596546-A1 | SULFONAMIDE COMPOUND, AND HARMFUL-ARTHROPOD EXTERMINATION COMPOSITION CONTAINING SAME | Sumitomo Chemical Company, Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-12378260-B2 | Benzotriazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| WO-1998040332-A1 | PROCESS FOR THE MANUFACTURE OF ARYLSULFONYL CHLORIDE | ZENECA LIMITED (GB) | 1998-09-17 | — | — | WO | disclosed |
| CN-1192739-A | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 1998-09-09 | — | — | CN | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| EP-0733629-A1 | Pyridonesulfonylurea compounds, process for their production and herbicides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5459138-A | Dysfunctions of glutamatergic neurotransmission associated with learning and memory | ADIR ET COMPAGNIE (FR) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | TRPV4 2582/4885NFE2L2 2094/4885LMNA 1044/4885 |
| US-20030162973-A1 | Process for the manufacture of arylsulfonyl chloride | TST, STS, DDC | TRPV4 2377/4885NFE2L2 1479/4885LMNA 4539/4885 |
| US-12378260-B2 | Benzotriazole compound | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885NFE2L2 1/4885LMNA 2933/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | TRPV4 1736/4885NFE2L2 1/4885LMNA 3058/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | TRPV4 3953/4885NFE2L2 2/4885LMNA 2817/4885 |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885NFE2L2 1/4885LMNA 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.